Poloxamer 407-induced atherogenesis in the C57BL/6 mouse

被引:97
|
作者
Palmer, WK
Emeson, EE
Johnston, TP
机构
[1] Univ Illinois, Sch Kinesiol MC 194, Exercise Res Div, Chicago, IL 60608 USA
[2] Univ Illinois, Coll Med, Dept Pathol, Chicago, IL 60608 USA
[3] Univ Missouri, Sch Pharm, Div Pharmaceut Sci, Kansas City, KS USA
关键词
aortic lesions; cholesterol; triglyceride; cholesterol diet; cholic acid; hyperlipidemia;
D O I
10.1016/S0021-9150(97)00193-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Poloxamer 407 (P-407) induces hyperlipidemia in the rat. It was the purpose of this investigation to determine if chronic P-407 administration would produce atherogenic arterial lesions in the C57BL/6 mouse, a strain reported to be susceptible to hyperlipidemia-induced atherosclerotic plaque formation. One injection (i.p.) of P-407 (0.5g/kg) produced hypercholesterolemia in the mouse that peaked at 24 h and returned to control levels by 96 h following treatment. Four groups of mice were maintained: (1) saline injected (C); (2) P-407-injected (0.5g/kg every 3rd day) (P); (3) P-407 injected plus cholic acid in the diet (PC); and (4) mice fed a high cholesterol (CHOL) diet containing cholic acid (HF). Mice from each group were sacrificed following 90, 145, 200, or 300 days of treatment. Plasma lipid concentrations, hepatic CHOL concentrations (145 and 300 day), and aortic atherogenic lesion areas were measured. Plasma CHOL and triglyceride remained at control levels throughout the 300 days in the C group. CHOL of the HF animals plateaued at approximately 225 mg/dl. P-407 produced CHOL concentrations of 600 mg/dl in P mice and 1000-1500 mg/dl in PC animals. There was no lesion formation in C mice. However, by 90 days lesions were present in the three other groups. Size of the lesions progressed through day 300 with the largest lesions (184.33 + 27.99 mu(2) x 10(-3)) being present in the PC mice. HF and P animals had lesions of 70.50 + 11.35 and 43.33 + 7.88 mu(2) x 10(-3), respectively. This study provides an animal model where atherogenesis has been produced with hyperlipidemia induced using a chemical agent. (C) 1998 Elsevier Science Ireland Ltd.
引用
收藏
页码:115 / 123
页数:9
相关论文
共 50 条
  • [1] Poloxamer 407-induced atherogenesis in the C57BL/6 mouse
    Johnston, TP
    Emeson, EE
    Palmer, WK
    CIRCULATION, 1997, 96 (08) : 3406 - 3406
  • [2] Regression of poloxamer 407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin
    Johnston, TP
    Baker, JC
    Hall, D
    Jamal, S
    Palmer, WK
    Emeson, EE
    ATHEROSCLEROSIS, 2000, 149 (02) : 303 - 313
  • [3] Sulfamethizole attenuates poloxamer 407-induced atherosclerotic neointima formation via inhibition of mTOR in C57BL/6 mice
    Solanki, Ankita
    Savla, Shreya R.
    Borkar, Maheshkumar R.
    Bhatt, Lokesh K.
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2023, 37 (05)
  • [4] MECHANISM OF POLOXAMER 407-INDUCED HYPERTRIGLYCERIDEMIA IN THE RAT
    JOHNSTON, TP
    PALMER, WK
    BIOCHEMICAL PHARMACOLOGY, 1993, 46 (06) : 1037 - 1042
  • [5] TRANSPLANTATION OF A PRIMARY MELANOMA INDUCED IN A C57BL/6 MOUSE
    HENNESSY, JM
    BERKELHAMMER, J
    CLINICAL RESEARCH, 1982, 30 (04): : A815 - A815
  • [6] ATHEROGENESIS IN UREMIC C57BL/6J MICE
    STEWARTPHILLIPS, JL
    GAGNON, RF
    LOUGH, J
    SOMERVILLE, P
    KIDNEY INTERNATIONAL, 1989, 35 (01) : 201 - 201
  • [7] Pharmacokinetic alterations in poloxamer 407-induced hyperlipidemic rats
    Lee, Unji
    Kwon, Mi Hye
    Kang, Hee Eun
    XENOBIOTICA, 2019, 49 (05) : 611 - 625
  • [8] The poloxamer 407-induced hyperlipidemic atherogenic animal model
    Palmer, WK
    Emeson, EE
    Johnston, TP
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 1997, 29 (11): : 1416 - 1421
  • [9] Poloxamer 407 as a general lipase inhibitor: its implications in lipid metabolism and atheroma formation in C57BL/6 mice
    Johnston, Thomas P.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2010, 62 (12) : 1807 - 1812
  • [10] Effects of nicotinic acid on poloxamer 407-induced hyperlipidemia
    Nash, VJ
    Johnston, TP
    Palmer, WK
    PHARMACOTHERAPY, 1996, 16 (01): : 10 - 15